Cantor Fitzgerald Starts Coverage on Lexeo Therapeutics with Strong Outlook
Cantor Fitzgerald initiates coverage of Lexeo Therapeutics with an Overweight rating, praising its cardiac gene therapy programs and transparent updates.
/ 2 items
Cantor Fitzgerald initiates coverage of Lexeo Therapeutics with an Overweight rating, praising its cardiac gene therapy programs and transparent updates.
Lexeo Therapeutics' gene therapy, LX2006, is moving faster toward FDA approval for Friedreich's ataxia cardiomyopathy.